Grandpharma has made interventional oncology products the fo...

Moomoo AI Oct 29, 2023 18:28

Grandpharma has made interventional oncology products the focus of the company's global strategy. The successful launch of LavaTM in the USA provides a new direction for the indications of Yttrium-90 microsphere injection. The company will increase investment in the research and development of anti-tumor nuclear medicine diagnosis and treatment to promote collaboration between investigational and marketed products.

Grandpharma (00512) has officially commercialized its innovative liquid embolic agent LavaTM in the United States, providing a new treatment option for peripheral artery bleeding.

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

See Original

Report

2715 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4829

Followers

Following

11K

Visitors